Hepatic farnesoid X receptor is necessary to facilitate ductular reaction and expression of heme biosynthetic genes

Background: Bile, which contains bile acids, the natural ligands for farnesoid x receptor (FXR), moves from the liver to the intestine through bile ducts. Ductular reaction often occurs during biliary obstruction. A subset of patients with erythropoietic protoporphyria, an inherited genetic mutation in heme biosynthetic enzyme ferrochelatase, accumulate porphyrin-containing bile plugs, leading to cholestasis. Here, we examined the link between FXR, bile plug formation, and how heme biosynthesis relates to this connection. Methods: We treated female and male wild-type and global and tissue-specific Fxr knockout mice with a diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine, an inhibitor of ferrochelatase, and examined the expression of heme biosynthetic genes. We mined FXR mouse ChIP-Seq data, performed biochemical and histological analysis, and tested HepG2 and primary human hepatocytes after treatment with obeticholic acid, an FXR agonist. Results: We observed that hepatic but not intestinal Fxr loss resulted in reduced bile plugs and ductular reaction in the liver. Then, we examined if FXR plays a regulatory role in heme biosynthesis and found significantly lower porphyrin accumulation in 3,5-diethoxycarbonyl-1, 4-dihydrocollidine–fed Fxr knockout mice. Gene expression and FXR mouse ChIP-Seq atlas analysis revealed that FXR orchestrates the expression of multiple heme biosynthetic enzymes. Finally, human HepG2 cells and primary human hepatocytes treated with obeticholic acid, showed increased expression of several heme biosynthetic genes. Conclusions: Overall, our data show that hepatic Fxr is necessary to maintain ductular reaction and accumulation of bile plugs. FXR can direct the expression of multiple heme biosynthetic genes. Thus, modulating FXR activity in EPP patients may help alleviate its associated liver disease.

[1]  S. Anakk,et al.  Loss Of Hepatic Small Heterodimer Partner Elevates Ileal Bile Acids And Alters Cell Cycle Related Genes In Male Mice. , 2022, Endocrinology.

[2]  G. Thallinger,et al.  Meta‐analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions , 2021, Hepatology communications.

[3]  M. Pollheimer,et al.  FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. , 2020, Journal of hepatology.

[4]  M. Balwani Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management. , 2019, Molecular genetics and metabolism.

[5]  M. Omary,et al.  Loss of hepatocyte β-catenin protects mice from experimental porphyria-associated liver injury. , 2019, Journal of hepatology.

[6]  S. Glaser,et al.  Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances , 2018, Hepatology.

[7]  H. Bonkovsky,et al.  Acute Hepatic Porphyrias: Review and Recent Progress , 2018, Hepatology communications.

[8]  J. Chiang F1000Prime recommendation of Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. , 2017 .

[9]  J. Boyer,et al.  Bile formation and secretion. , 2013, Comprehensive Physiology.

[10]  F. Baldelli,et al.  Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[12]  A. Gouw,et al.  Ductular reactions in human liver: Diversity at the interface , 2011, Hepatology.

[13]  M. Omary,et al.  Gender dimorphic formation of Mallory‐Denk bodies and the role of xenobiotic metabolism and oxidative stress , 2010, Gastroenterology.

[14]  K. Zatloukal,et al.  Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. , 2009, The American journal of pathology.

[15]  M. Worwood,et al.  Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. , 2007, Blood.

[16]  M. Zavolan,et al.  Regulation of human liver δ‐aminolevulinic acid synthase by bile acids , 2007 .

[17]  S. Khorasanizadeh,et al.  Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ , 2007, Nature Structural &Molecular Biology.

[18]  K. Zatloukal,et al.  A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. , 2007, The American journal of pathology.

[19]  R. Evans,et al.  Benefit of farnesoid X receptor inhibition in obstructive cholestasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Phillips,et al.  Biosynthesis of heme in mammals. , 2006, Biochimica et biophysica acta.

[21]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[22]  P. Dawson,et al.  OSTα‐OSTβ: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia , 2005 .

[23]  Jiandie D. Lin,et al.  Nutritional Regulation of Hepatic Heme Biosynthesis and Porphyria through PGC-1α , 2005, Cell.

[24]  Andrew G Smith,et al.  Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool. , 2005, The American journal of pathology.

[25]  R. Savkur,et al.  Regulation of carbohydrate metabolism by the farnesoid X receptor. , 2005, Endocrinology.

[26]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[27]  B. Staels,et al.  Glucose regulates the expression of the farnesoid X receptor in liver. , 2004, Diabetes.

[28]  U. Meyer,et al.  Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Activate a Drug-responsive Enhancer of the Murine 5-Aminolevulinic Acid Synthase Gene* , 2003, Journal of Biological Chemistry.

[29]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[30]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[31]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[32]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[33]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[34]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[35]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[36]  M. Doss,et al.  Hepatic complications of erythropoietic protoporphyria * , 1998, Photodermatology, photoimmunology & photomedicine.

[37]  D. Todd Erythropoietic protoporphyria , 1994, The British journal of dermatology.

[38]  J. Deybach,et al.  Ferrochelatase structural mutant (Fechm1Pas) in the house mouse. , 1993, Genomics.

[39]  B. May,et al.  Identification of regulatory sequences in the gene for 5-aminolevulinate synthase from rat. , 1993, The Journal of biological chemistry.

[40]  J. Guénet,et al.  Erythropoietic protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. , 1991, The Journal of clinical investigation.

[41]  J. Bloomer The liver in protoporphyria , 1988, Hepatology.

[42]  J. Marin,et al.  Effect of bile acids on hepatic protoporphyrin metabolism in perfused rat liver. , 1987, Gastroenterology.

[43]  A. Kappas,et al.  Porphyrin-Heme Pathway: Regulation by Intermediates in Bile Acid Synthesis , 1973, Science.

[44]  R. Schmid,et al.  Metabolic regulation of heme catabolism and bilirubin production. I. Hormonal control of hepatic heme oxygenase activity. , 1972, The Journal of clinical investigation.

[45]  C. Rimington,et al.  Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. , 1961, Lancet.

[46]  F. Figge,et al.  Porphyrin Metabolism in Mice Following Quantitative Administration of Collidine Compounds and Oxidation Products , 1960 .

[47]  H. M. Solomon,et al.  Disturbance in Porphyrin Metabolism Caused by Feeding Diethyl 1, 4-dihydro-2, 4, 6-trimethylpyridine-3, 5-dicarboxylate , 1959, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[48]  Gerhard G Thallinger,et al.  A Comprehensive FXR Signaling Atlas Derived from Pooled ChIP-seq Data , 2019, dHealth.

[49]  J. Boyer,et al.  Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST (cid:1) -OST (cid:2) in cholestasis in humans and rodents , 2006 .

[50]  J. van Hattum,et al.  Chenodeoxycholic acid therapy in erythrohepatic protoporphyria. , 1986, Journal of hepatology.